Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

Fig. 2

The molecular and genetic characteristics of different types of compound EGFR mutations. A The lollipop plots of EGFR VUSs from various VUS-containing compound EGFR mutations, including L858R + VUSs (n = 416), 19-Del + VUSs (n = 86), and rare + VUSs (n = 185). B The percentage of patients with various mutated genes stratified by different compound EGFR mutation types. Patients’ samples that were characterized by targeted NGS of 139 key lung cancer-related genes were included in the analysis (n = 720). C The percentage of patients with various altered signaling pathways stratified by different compound EGFR mutation types. Patients’ samples that were characterized by targeted NGS of 139 key lung cancer-related genes were included in the analysis (n = 720). The Kruskal–Wallis test was conducted to compare multiple groups. P-value of < 0.05 was considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). SP, signal peptide; TM, transmembrane domain

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us